The side effects of Defibrotide mainly include bleeding tendency, gastrointestinal reactions, and allergic reactions, most of which can be alleviated by adjusting the medication regimen or symptomatic treatment. The following is an explanation of common side effects classification and specific mitigation measures.

1. Bleeding related side effects

(1) Common manifestations

The incidence of mild bleeding such as nosebleeds and gum bleeding is about 15%, while the incidence of severe bleeding such as gastrointestinal bleeding is less than 5%.

(2) Mitigation measures

Use a soft bristled toothbrush to avoid gum damage; Avoid strenuous exercise and external injuries; Regularly monitor platelet and coagulation function.

2 Digestive system reactions

(1) Common manifestations

Nausea (12% -18%) and diarrhea (9% -15%) are mostly mild and usually resolve on their own after 1-2 weeks of medication.

(2) Mitigation measures

Suggest taking medication after meals; Electrolytes can be supplemented during diarrhea; Persistent symptoms require consideration of reducing or suspending medication.

3 Allergic reactions

(1) Common manifestations

Skin rash (3% -7%), facial edema and other hypersensitivity reactions often occur within 1 hour after the first administration.

(2) Mitigation measures

Prepare antihistamines before medication; Severe allergies require immediate discontinuation of medication and treatment with adrenaline.

4 Other precautions

(1) Abnormal liver function

The incidence of elevated ALT is about 8%. It is recommended to monitor liver function weekly and adjust the dosage if necessary.

(2) Drug interactions

Avoid using anticoagulant/antiplatelet drugs in combination, and closely monitor coagulation function if necessary.

5. Storage conditions for original packaging

(1) Unfolded freeze-dried powder

It needs to be stored in a refrigerated environment at 2-8 ° C, keeping the original packaging in a dark state. Freezing or exposure to high temperatures is prohibited, similar to the storage requirements of Dedobutuzumab.

(2) Oral preparations

Tablets/capsules should be stored at room temperature (20-25 ° C) in their original packaging to avoid moisture; Oral liquids should be stored at 2-25 ° C and used within 60 days after the first opening, in accordance with the Ibrutinib Suspension Management Standard.